Pfizer Working To Catch Up In NASH With Fat-Reducing Compounds

 
• By Joseph Haas
  
Generate a summary of this article
Listen to this article
Beta

Just moving into Phase II with a pair of candidates, Pfizer trails smaller rivals in the NASH race, but the deep-pocked firm may have the assets to develop its own proprietary combination therapy for the large-scale unmet medical need.

Morrie Birnbaum of Pfizer
Pfizer Chief Scientific Officer, Internal Medicine, Morris Birnbaum

Pfizer Inc.’s R&D efforts in non-alcoholic steatohepatitis (NASH) have been going on for about six and a half years, but the pharma only presented its first clinical data for a NASH candidate at the 2018 International Liver Conference in April. The company is advancing three clinical candidates for NASH, with a diabetes candidate also possibly offering potential in the unmet medical need, with a focus on reducing fat in the liver and the hope that other aspects of the disease will show benefit as well.

“Because we're operating [the program] out of a metabolic unit and that's our bias as well as our expertise, we...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from R&D

  • ProGen’s Dual Agonist Obesity Contender Gains Momentum With Rani Partnership

     
    • By Jung Won Shin

    The CEO of South Korean biotech shares how his company was able to reach a partnership with Rani so quickly and why it is confident in its GLP-1/GLP-2 dual agonist for obesity and diabetes, despite recent disappointing clinical results for its sole rival.

  • Sciwind Eyes Differentiation For Ecnoglutide In Highly Competitive Arena

     
    • By Xu Hu

    Chinese firm Sciwind has revealed additional Phase III findings for its promising once-weekly GLP-1 agonist ecnoglutide, just one asset in a burgeoning Chinese sector that could see the emergence of new rivals to current global leaders in obesity and diabetes.

  • Fosun ALK/ROS1 Inhibitor Shows 1L Promise In Advanced NSCLC

     
    • By Xu Hu

    Interim results from the Phase III REMARK study presented at WCLC showed the Chinese company’s second-generation ALK/ROS1 inhibitor met its primary endpoint as a first-line therapy in ALK-positive advanced NSCLC.

  • Sponsored By:

    Nancy Tests SPARC-931-part

    The article discusses the impact of upcoming patent expirations in oncology biologics on biosimilar developers, highlighting the opportunities in Antibody-Drug Conjugates (ADCs) and Bispecific Antibodies (BsAbs). It explores the challenges posed by the structural complexities of these biologics, necessitating new bioanalytical tools and manufacturing processes. The evolving regulatory landscape, with contributions from EMA, FDA, and WHO, offers flexible pathways but also presents challenges. The article underscores the potential for biosimilars to generate significant cost savings and enhance patient access to cancer treatments over the next decade.

More from Scrip